Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 41Carcinoma, Renal Cell 32Neuroendocrine Tumors 15Neoplasms 12Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 8Carcinoma 7Tuberous Sclerosis 6Kidney Neoplasms 5Carcinoma, Hepatocellular 5Carcinoid Tumor 5Lymphoma 4Adenoma, Islet Cell 4Stomach Neoplasms 3Recurrence 3Pancreatic Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Lymphangioleiomyomatosis 3Lung Neoplasms 3Colorectal Neoplasms 3Angiomyolipoma 3Adenocarcinoma 3von Hippel-Lindau Disease 2Triple Negative Breast Neoplasms 2Seizures 2Neuroectodermal Tumors, Primitive 2Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2

Interventions

varlilumab 1Interferon alpha-2 1Everolimus 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Margins of Excision × Everolimus × Clear all
NCT00719264 2017-03-20

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Novartis

Phase 2 Completed
365 enrolled 14 charts
Genitourinary

Margins of Excision, Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡